Dr.ย Patrickย Hwu
MD, Board Certified in Medical Oncology
Medical Oncologist & Tumour Immunologist
corporate_fareMoffitt Cancer Center, Tampa, Florida
Patrick Hwu
MD, Board Certified in Medical Oncology
Dr. Patrick Hwu is an American medical oncologist, tumour immunologist, and physician-scientist who serves as President and Chief Executive Officer of Moffitt Cancer Center in Tampa, Florida. He is internationally recognised for his work in cancer immunotherapy, with a clinical focus on melanoma and a research focus on T-cell-based therapies.
Dr. Hwu's career has been closely tied to the rise of modern cancer immunotherapy. Working at the National Cancer Institute in the early 1990s alongside Dr. Steven Rosenberg, he helped demonstrate that human T cells could be genetically engineered to recognise and attack cancer, and he published research on the first chimeric antigen receptor (CAR) directed against cancer. Before joining Moffitt in 2020, he spent 17 years at The University of Texas MD Anderson Cancer Center, where he was the first chair of Melanoma Medical Oncology and later Head of the Division of Cancer Medicine. His research spans melanoma immunotherapy, adoptive T-cell and TIL therapy, cancer vaccines, cytokine biology, and mechanisms of immune resistance. He continues to treat melanoma patients and maintains his own research laboratory while leading Moffitt.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion at a major comprehensive cancer centre.
Why Consider Dr. Patrick Hwu?
Dr. Hwu combines decades of immunotherapy research with leadership of one of the United States' major comprehensive cancer centres.
Areas of Specialisation
Melanoma, cancer immunotherapy, and cell-based therapy
Dr. Hwu's clinical and research work centres on using the immune system to treat cancer, particularly melanoma and other advanced solid tumours.
Cancer Immunotherapy
Immune-based approaches that help the immune system recognise and attack cancer cells.
- arrow_rightPD-1 and CTLA-4 checkpoint inhibitor strategies for melanoma
- arrow_rightManagement of immunotherapy-resistant and progressing disease
- arrow_rightResearch into tumour vaccine approaches
- arrow_rightStudy of mechanisms behind tumour immune escape
Adoptive Cell Therapy
Personalised therapies that use a patient's own immune cells to fight cancer.
- arrow_rightAdoptive T-cell therapy using tumour-derived immune cells
- arrow_rightParticularly relevant in advanced melanoma after prior systemic therapy
- arrow_rightFoundational work on engineering T cells to recognise cancer
- arrow_rightResearch directions connected to CAR T-cell therapy development
Procedures Performed
Clinical services and treatment approaches
Dr. Hwu's clinical work focuses on systemic and immune-based treatment of melanoma and advanced solid tumours, supported by expert case review.
Immunotherapy & Systemic Treatment
Medical OncologyImmune-based and systemic treatment planning for melanoma and advanced solid tumours.
Advanced & Cell Therapy Evaluation
Complex DiseaseAssessment of patients with complex or treatment-resistant disease for advanced and cell-based therapy pathways.
Multidisciplinary Cancer Care
MultidisciplinaryCoordinated treatment planning across surgical, radiation, medical, and cellular therapy teams.
Second Opinion Consultations
Second OpinionIndependent expert review of melanoma and advanced solid tumour cases.
Research & Publications
Tumour immunology and cell therapy research
Dr. Hwu has authored or contributed to a large body of peer-reviewed research in tumour immunology, melanoma immunotherapy, and cell-based cancer treatment.
A more detailed publication list may be available on request through CancerFax.
Education & Training
Dr. Hwu trained at leading United States medical and research institutions, with a foundation in internal medicine, medical oncology, and tumour immunology.
Clinical Experience
Dr. Hwu's career spans the National Cancer Institute, MD Anderson Cancer Center, and Moffitt Cancer Center, combining research leadership, clinical oncology, and executive leadership.
Languages & International
Dr. Hwu consults in the following language.
CancerFax can coordinate professional medical interpreter support for international patients seeking an opinion at a United States cancer centre.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Patrick Hwu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Patrick Hwu's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Patrick Hwu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Patrick Hwu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Patrick Hwu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Patrick Hwu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Patrick Hwu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Patrick Hwu
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion connected to Dr. Hwu's centre, subject to hospital availability and case acceptance. Final decisions rest with the treating institution.
Dr. Hwu is a medical oncologist and tumour immunologist with a clinical focus on melanoma and a research focus on cancer immunotherapy, including TIL therapy, adoptive T-cell therapy, cancer vaccines, and immune resistance.
Yes. Dr. Hwu is internationally recognised for his work in T-cell-based cancer therapy and leads Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center with a large cell therapy programme. TIL therapy requires careful eligibility assessment and must be delivered at experienced cell therapy centres.
Submit your medical reports through CancerFax. The team will review the documents, prepare a structured case summary, and coordinate the next steps with the hospital, subject to availability. A second-opinion request should include pathology reports, BRAF mutation status, imaging, and treatment history.
Helpful records include the diagnosis summary, biopsy and histopathology reports, IHC and molecular testing, BRAF mutation status, NGS report if available, PET-CT, CT or MRI scans, prior immunotherapy and targeted therapy history, and current medications. CancerFax can help organise these into a specialist-ready summary.
Connect with Patrick Hwu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.